Get started
Work

A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma

Year: 2014
Type: article
Abstract: Natural killer (NK) cells are involved in immune surveillance of various malignancies, including multiple myeloma (MM).[1][1] IPH2101 is a fully human monoclonal antibody that blocks HLA-C binding KIR2D receptors (KIR2DL/DS-1, -2 -3) expressed on the surface of NK-cells, enhancing their cytotoxicity
DOI: 10.3324/haematol.2013.103085
Authors: N. Korde, M. Carlsten, M.-J. Lee, A. Minter, E. Tan, M. Kwok, E. Manasanch, M. Bhutani, N. Tageja, M. Roschewski, A. Zingone, R. Costello, M. Mulquin, D. Zuchlinski, I. Maric, K. R. Calvo, R. Braylan, P. Tembhare, C. Yuan, M. Stetler-Stevenson, J. Trepel, R. Childs, O. Landgren
Institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research, National Heart, Lung, and Blood Institute, Walter Reed National Military Medical Center, National Institutes of Health Clinical Center, Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,157
OpenAlex ID: W2018580749
FWCI: 8.188
Cites: 14
Cited by: 131
Related to: 10